Russian government to abolish procedure of mandatory certification

11 December 2019

The Russian government has officially approved a new procedure for commercialization of drugs in the national pharmaceutical market, according to recent statements made by some senior state officials of the Russian Ministry of Health and local analysts, reports The Pharma Letter’s local correspondent.

The adoption of the new procedure also became part of a recent decree, signed by Russia’s Prime Minister Dmitry Medvedev and according to which the drugs that are launched in the Russian market, will no longer be a subject of mandatory certification.

Instead of this, manufacturers will be obliged to apply for permissions for the launch of their drugs in Russia to the Federal Service for Health Supervision of Russia (Roszdravnadzor).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK